[go: up one dir, main page]

MX2019008460A - Metodos para tratar esclerosis multiple usando celulas t autologas. - Google Patents

Metodos para tratar esclerosis multiple usando celulas t autologas.

Info

Publication number
MX2019008460A
MX2019008460A MX2019008460A MX2019008460A MX2019008460A MX 2019008460 A MX2019008460 A MX 2019008460A MX 2019008460 A MX2019008460 A MX 2019008460A MX 2019008460 A MX2019008460 A MX 2019008460A MX 2019008460 A MX2019008460 A MX 2019008460A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
autologous
methods
cells
treat multiple
Prior art date
Application number
MX2019008460A
Other languages
English (en)
Inventor
Khanna Rajiv
Smith Corey
Tolu Aftab Blake
Original Assignee
Atara Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atara Biotherapeutics Inc filed Critical Atara Biotherapeutics Inc
Publication of MX2019008460A publication Critical patent/MX2019008460A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)

Abstract

Se proporcionan en la presente composiciones y metodos relacionados con el tratamiento de esclerosis multiple en un sujeto.
MX2019008460A 2017-01-20 2018-01-19 Metodos para tratar esclerosis multiple usando celulas t autologas. MX2019008460A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448707P 2017-01-20 2017-01-20
US201762576349P 2017-10-24 2017-10-24
PCT/US2018/014458 WO2018136762A1 (en) 2017-01-20 2018-01-19 Methods of treating multiple sclerosis using autologous t cells

Publications (1)

Publication Number Publication Date
MX2019008460A true MX2019008460A (es) 2019-12-02

Family

ID=62909271

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008460A MX2019008460A (es) 2017-01-20 2018-01-19 Metodos para tratar esclerosis multiple usando celulas t autologas.
MX2025003245A MX2025003245A (es) 2017-01-20 2019-07-15 Metodos para tratar esclerosis multiple usando celulas t autologas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025003245A MX2025003245A (es) 2017-01-20 2019-07-15 Metodos para tratar esclerosis multiple usando celulas t autologas

Country Status (13)

Country Link
US (2) US20190350981A1 (es)
EP (1) EP3570852B1 (es)
JP (3) JP7726625B2 (es)
KR (2) KR20250067948A (es)
CN (1) CN110430886A (es)
AU (1) AU2018210375B2 (es)
BR (1) BR112019014406A2 (es)
CA (1) CA3050299A1 (es)
MX (2) MX2019008460A (es)
RU (1) RU2769474C2 (es)
SG (1) SG11201906097VA (es)
TW (1) TWI868049B (es)
WO (1) WO2018136762A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109477830A (zh) 2016-05-25 2019-03-15 昆士兰医学研究所理事会 免疫疗法的方法
CA3050299A1 (en) * 2017-01-20 2018-07-26 Atara Biotherapeutics, Inc. Methods of treating multiple sclerosis using autologous t cells
US20210380657A1 (en) * 2018-10-25 2021-12-09 The Council Of The Queensland Institute Of Medical Research T-Cell Receptors and Uses Thereof
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20020009448A1 (en) * 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
NZ517959A (en) * 1999-09-30 2004-05-28 Univ Washington Pharmaceutical compositions comprising herpes simplex virus (HSV) proteins ICP0 or UL47 and a method producing immune cells with the proteins
US7670781B2 (en) 2002-01-03 2010-03-02 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
US7695713B2 (en) * 2002-08-08 2010-04-13 Baylor College Of Medicine Isolation and identification of T cells
AU2004281817B2 (en) * 2003-10-17 2010-07-22 Baylor College Of Medicine A method for increasing CD8+ cytotoxic T cell reponses and for treating multiple sclerosis
PT3320912T (pt) * 2008-04-17 2021-05-24 Io Biotech Aps Imunoterapia à base de indoleamina 2,3-dioxigenase
EP2689009A1 (en) * 2011-03-25 2014-01-29 TXCell Method for using regulatory t cells in therapy
CN109182266A (zh) 2011-12-12 2019-01-11 细胞药物有限公司 扩大t细胞的方法
CN111733131A (zh) * 2013-07-15 2020-10-02 美国卫生和人力服务部 制备抗人乳头瘤病毒抗原的t细胞的方法
RU2558294C1 (ru) * 2014-09-16 2015-07-27 Общество с ограниченной ответственностью "НекстГен" Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека
SG10201913613SA (en) * 2015-05-28 2020-03-30 Kite Pharma Inc Methods of conditioning patients for t cell therapy
AU2017271134A1 (en) * 2016-05-25 2019-01-03 The Council Of The Queensland Institute Of Medical Research Methods of treating autoimmune disease using allogeneic t cells
CN109477830A (zh) * 2016-05-25 2019-03-15 昆士兰医学研究所理事会 免疫疗法的方法
CA3050299A1 (en) * 2017-01-20 2018-07-26 Atara Biotherapeutics, Inc. Methods of treating multiple sclerosis using autologous t cells
US20230210984A1 (en) * 2019-10-23 2023-07-06 The Council Of The Queensland Institute Of Medical Research Adoptive immunotherapy

Also Published As

Publication number Publication date
NZ755116A (en) 2024-03-22
RU2019124454A (ru) 2021-02-20
JP2025098005A (ja) 2025-07-01
TWI868049B (zh) 2025-01-01
US20250270272A1 (en) 2025-08-28
AU2018210375A1 (en) 2019-07-25
JP2020506901A (ja) 2020-03-05
US20190350981A1 (en) 2019-11-21
TW201840327A (zh) 2018-11-16
JP7726625B2 (ja) 2025-08-20
WO2018136762A1 (en) 2018-07-26
SG11201906097VA (en) 2019-08-27
EP3570852A1 (en) 2019-11-27
KR20250067948A (ko) 2025-05-15
JP2023052033A (ja) 2023-04-11
AU2018210375B2 (en) 2024-04-04
MX2025003245A (es) 2025-04-02
CA3050299A1 (en) 2018-07-26
BR112019014406A2 (pt) 2020-04-28
KR20190124214A (ko) 2019-11-04
RU2769474C2 (ru) 2022-04-01
EP3570852B1 (en) 2025-07-30
EP3570852A4 (en) 2020-08-05
CN110430886A (zh) 2019-11-08
RU2019124454A3 (es) 2021-10-01

Similar Documents

Publication Publication Date Title
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
MX2024012899A (es) Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias
MX2022010805A (es) Metodo para reducir la neutropenia.
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
CL2018001652A1 (es) Composiciones y métodos para disminuir la expresión de tau
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
CL2018003284A1 (es) Métodos de tratamiento de enfermedades autoinmunes usando linfocitos t alogénicos.
CL2017002050A1 (es) Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
BR112018009706A8 (pt) composições compreendendo cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
MX375352B (es) Reguladores de nrf2.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX2017003262A (es) Composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2020003762A (es) Composiciones cosmeticas y metodo para tratar la piel.
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
MX2017000374A (es) Metodos y composiciones que regulan el crecimiento del pelo.
MX2019008460A (es) Metodos para tratar esclerosis multiple usando celulas t autologas.